AGEs/sRAGE, a novel risk factor in the pathogenesis of end-stage renal disease

被引:35
作者
Prasad, Kailash [1 ]
Dhar, Indu [1 ]
Zhou, Qifeng [2 ,3 ]
Elmoselhi, Hamdi [2 ,3 ]
Shoker, Muhammad [1 ]
Shoker, Ahmed [2 ,3 ]
机构
[1] Univ Saskatchewan, Dept Physiol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada
[2] Univ Saskatchewan, Coll Med, Dept Med, Saskatoon, SK, Canada
[3] Univ Saskatchewan, Royal Univ Hosp, Saskatoon, SK, Canada
关键词
Advanced glycation end products (AGEs); Soluble receptors for AGE; sRAGE; esRAGE; cRAGE; AGEs/sRAGE; Inflammation; End-stage renal disease; CIRCULATING SOLUBLE RECEPTOR; CHRONIC KIDNEY-DISEASE; SERUM-LEVELS; CARDIOVASCULAR-DISEASE; PLASMA-LEVELS; PRODUCTS; ATHEROSCLEROSIS; RAGE; ASSOCIATION; AGE;
D O I
10.1007/s11010-016-2829-4
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Interaction of advanced glycation end products (AGEs) with its cell-bound receptor (RAGE) results in cell dysfunction through activation of nuclear factor kappa-B, increase in expression and release of inflammatory cytokines, and generation of oxygen radicals. Circulating soluble receptors, soluble receptor (sRAGE), endogenous secretory receptor (esRAGE) and cleaved receptor (cRGAE) act as decoy for RAGE ligands and thus have cytoprotective effects. Low levels of sRAGE and esRAGE have been proposed as biomarkers for many diseases. However sRAGE and esRAGE levels are elevated in diabetes and chronic renal diseases and still tissue injury occurs. It is possible that increases in levels of AGEs are greater than increases in the levels of soluble receptors in these two diseases. Some new parameters have to be used which could be an universal biomarkers for cell dysfunction. It is hypothesized that increases in serum levels of AGEs are greater than the increases in the soluble receptors, and that the levels of AGEs is correlated with soluble receptors and that the ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE are elevated in patients with end-stage renal disease (ESRD) and would serve as an universal risk marker for ESRD. The study subject comprised of 88 patients with ESRD and 20 healthy controls. AGEs, sRAGE and esRAGE were measured using commercially available enzyme linked immune assay kits. cRAGE was calculated by subtracting esRAGE from sRAGE. The data show that the serum levels of AGEs, sRAGE, cRAGE are elevated and that the elevation of AGEs was greater than those of soluble receptors. The ratios of AGEs/sRAGE, AGEs/esRAGE and AGEs/cRAGE were elevated and the elevation was similar in AGEs/sRAGE and AGEs/cRAGE but greater than AGEs/esRAGE. The sensitivity, specificity, accuracy, and positive and negative predictive value of AGEs/sRAGE and AGEs/cRAGE were 86.36 and 84.88 %, 86.36 and 80.95 %, 0.98 and 0.905, 96.2 and 94.8 %, and 61.29 and 56.67 % respectively. There was a positive correlation of sRAGE with esRAGE and cRAGE, and AGEs with esRAGE; and negative correlation between sRAGE and AGEs/sRAGE, esRAGE and AGES/esRAGE, and cRAGE and AGES/cRAGE. In conclusion, AGEs/sRAGE, AGEs/cRAGE and AGEs/esRAGE may serve as universal risk biomarkers for ESRD and that AGEs/sRAGE and AGEs/cRAGE are better risk biomarkers than AGEs/esRAGE.
引用
收藏
页码:105 / 114
页数:10
相关论文
共 50 条
  • [21] Cardiovascular risk in diabetic end-stage renal disease patients
    Wang, Angela Yee-Moon
    JOURNAL OF DIABETES, 2011, 3 (02) : 119 - 131
  • [22] The challenge of cardiovascular risk factors in end-stage renal disease
    Covic, A
    Gusbeth-Tatomir, P
    Goldsmith, DJA
    JOURNAL OF NEPHROLOGY, 2003, 16 (04) : 476 - 486
  • [23] The risk for end-stage renal disease is increased after burn
    Helantera, Ilkka
    Koljonen, Virve
    Finne, Patrik
    Tukiainen, Erkki
    Gissler, Mika
    BURNS, 2016, 42 (02) : 316 - 321
  • [24] The Pathogenesis of End-Stage Renal Disease from the Standpoint of the Theory of General Pathological Processes of Inflammation
    Gusev, Evgenii
    Solomatina, Liliya
    Zhuravleva, Yulia
    Sarapultsev, Alexey
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (21)
  • [25] Cumulative hypertension burden and risk of end-stage renal disease
    Kim, Chang Seong
    Kim, Bongseong
    Choi, Hong Sang
    Bae, Eun Hui
    Ma, Seong Kwon
    Han, Kyung-Do
    Kim, Soo Wan
    HYPERTENSION RESEARCH, 2021, 44 (12) : 1652 - 1661
  • [26] Increased risk of deep vein thrombosis in end-stage renal disease patients
    Lu, Hsueh-Yi
    Liao, Kuang-Ming
    BMC NEPHROLOGY, 2018, 19
  • [27] Diagnostic performance of computed tomographic coronary angiography in patients with end-stage renal disease
    Jug, Borut
    Papazian, Jenny
    Gupta, Mohit
    Bhatia, Harpreet
    Derakhshani, Arya
    Koplik, Sheri
    Karlsberg, Ronald P.
    Budoff, Matthew J.
    CORONARY ARTERY DISEASE, 2013, 24 (02) : 135 - 141
  • [28] Cardiac risk assessment for end-stage renal disease patients on the renal transplant waiting list
    Tabriziani, Hossein
    Baron, Pedro
    Abudayyeh, Islam
    Lipkowitz, Michael
    CLINICAL KIDNEY JOURNAL, 2019, 12 (04) : 576 - 585
  • [29] Sleep apnea in end-stage renal disease patients: risk factors and mortality
    Prabu, Pranav
    Acree, Lillian
    Waller, Jennifer L.
    Linder, Daniel F.
    Bollag, Wendy B.
    Mohammed, Azeem
    Padala, Sandeep
    Healy, William
    Kheda, Mufaddal
    Baer, Stephanie L.
    Dillard, Thomas
    Taskar, Varsha
    JOURNAL OF INVESTIGATIVE MEDICINE, 2023, 71 (05) : 465 - 470
  • [30] End-Stage Renal Disease and Pregnancy
    Nadeau-Fredette, Annie-Claire
    Hladunewich, Michelle
    Hui, Dini
    Keunen, Johannes
    Chan, Christopher T.
    ADVANCES IN CHRONIC KIDNEY DISEASE, 2013, 20 (03) : 246 - 252